Hims latest offering, Grail's Galleri cancer test, fails U.K. study
Source: SeekingAlpha
2026-02-20 13:25:16 ET
More on Hims & Hers Health, GRAIL, Inc.
- GRAIL, Inc. (GRAL) Q4 2025 Earnings Call Transcript
- What Is HIMS Worth Without GLP-1? Earnings Preview
- Hims & Hers Health: 5 Key Questions Ahead Of Critical Q4 Earnings
- Grail slides as trial misses primary endpoint, fails to show significant stage III-IV cancer reduction
- GRAIL reiterates 22%-32% Galleri sales growth guidance for 2026 while expanding sales force after NHS-Galleri trial
Read the full article on Seeking Alpha
For further details see:
Hims latest offering, Grail's Galleri cancer test, fails U.K. study
Illumina Inc.
NASDAQ: ILMN
ILMN Trading
-1.46% G/L:
$120.935 Last:
604,601 Volume:
$122 Open:
ILMN Latest News
March 05, 2026 09:15:00 am
Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering
February 27, 2026 09:15:00 am
Illumina whole-genome sequencing technology to accelerate rare disease testing in Florida
February 25, 2026 09:15:00 am
Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics
February 24, 2026 12:15:00 pm
Illumina launches TruPath Genome, setting a new standard in genomic insight
ILMN Stock Data
$18,085,408,000
148,827,200
0.13%
404
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
